Mary Lynne Hedley has sold stock and made no open-market buys since Mar 2017

Dr. Mary Lynne Hedley is a biotech and pharmaceutical executive and immunologist with more than 25 years of experience leading the development and commercialization of new medicines, particularly in oncology.( She serves as a director of Veeva Systems Inc. (NYSE: VEEV), where she sits on the board of directors and receives equity-based compensation as a corporate insider.( In addition to her role at Veeva, Hedley is a senior scientific fellow and strategic advisor at the Broad Institute of MIT and Harvard and a venture partner at Third Rock Ventures, reflecting her ongoing leadership in early-stage therapeutics and translational science.(

Hedley co‑founded TESARO, Inc., an oncology-focused biotechnology company, and served as its president, chief operating officer, director, and chief scientific officer until its acquisition by GSK, overseeing R&D, global manufacturing and operations, portfolio management, and commercial strategy.( Earlier in her career she held senior executive roles including executive vice president and chief scientific officer at Abraxis BioScience, executive vice president at Eisai Corporation of North America following its acquisition of MGI PHARMA, and founding president and CEO of ZYCOS, Inc., which was acquired by MGI PHARMA.( She sits or has sat on multiple boards, including Eli Lilly and Company, Centessa Pharmaceuticals, Helsinn Healthcare, and other life sciences organizations.( Hedley earned a B.S. in microbiology from Purdue University and a Ph.D. in molecular and cellular immunology from the University of Texas Southwestern Medical Center, followed by postdoctoral fellowships in immunology and gene regulation at Harvard University.(

Written by Perplexity from public sources.